Filing Flows › Comparisons › PTHS vs CHRS
Pelthos Therapeutics vs Coherus Oncology: PTHS and CHRS compared
Pelthos Therapeutics is the larger company: $15.6M of revenue in its latest quarter (Q2 2026) against $14.3M for Coherus Oncology (Q2 2026). Pelthos Therapeutics is more profitable, with an operating margin of -111.0% against -226.0%.
Where the money goes: PTHS and CHRS
Pelthos Therapeutics (PTHS) · Q2 2026
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Coherus Oncology (CHRS) · Q2 2026
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
| Pelthos Therapeutics (PTHS) | Coherus Oncology (CHRS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $15.6M | $14.3M |
| Revenue growth, Y/Y | — | +40% |
| Operating margin | -111.0% | -226.0% |
| Net earnings | −$23.4M | −$20.6M |
| Net margin | -150.1% | -144.2% |
| Operating cash flow | −$7.7M | −$62.1M |
Where the revenue comes from
Pelthos Therapeutics
- Net product revenues: $15.4M (99%)
- License and collaboration revenues: $183K (1%)
Coherus Oncology
- Toripalimab: $13.6M (95%)
- Other revenue: $694K (5%)
Questions
Which is bigger, Pelthos Therapeutics or Coherus Oncology?
Pelthos Therapeutics is the larger company: $15.6M of revenue in its latest quarter (Q2 2026) against $14.3M for Coherus Oncology (Q2 2026).
Is Pelthos Therapeutics or Coherus Oncology growing faster?
Pelthos Therapeutics is more profitable, with an operating margin of -111.0% against -226.0%.
More: Pelthos Therapeutics earnings · how Pelthos Therapeutics makes money · Coherus Oncology earnings · how Coherus Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.